Biogen Inc
NAS : BIIB$232.65+1.76%Oct 16 close
Financials
A full-history view is not available for the cash flow statement yet. This is the statement exactly as one filing printed it.
Consolidated Statements of Cash Flows
USD · reported units. Click a value to inspect its source.
| Reported line item | Jan 1, 2025 to Dec 31, 2025 (current) | Jan 1, 2024 to Dec 31, 2024 | Jan 1, 2023 to Dec 31, 2023 |
|---|---|---|---|
| Net income | |||
| Depreciation and amortization | |||
| Impairment of intangible assets | |||
| Impairment of ROU asset | |||
| Excess and obsolescence charges related to inventory | |||
| Amortization of acquired inventory step-up | |||
| Acquired in-process research and development | |||
| Share-based compensation | |||
| Contingent consideration | |||
| Deferred income taxes | |||
| (Gain) loss on strategic investments | |||
| Gain on sale of priority review voucher, net | |||
| Other | |||
| Accounts receivable | |||
| Due from anti-CD20 therapeutic programs | |||
| Inventory | |||
| Accrued expense and other current liabilities | |||
| Income tax assets and liabilities | |||
| Other changes in operating assets and liabilities, net | |||
| Net cash flow provided by (used in) operating activities | |||
| Purchases of property, plant and equipment | |||
| Proceeds from sales and maturities of marketable securities | |||
| Purchases of marketable securities | |||
| Acquisition, net of cash acquired | — | — | |
| Proceeds from sale of equity interest in Samsung Bioepis | |||
| Proceeds from sale of priority review voucher, net | |||
| Acquired in-process research and development | |||
| Acquisitions of intangible assets | |||
| Proceeds from sales of strategic investments | |||
| Other | |||
| Net cash flow provided by (used in) investing activities | |||
| Payments related to issuance of stock for share-based compensation arrangements, net | |||
| Proceeds from borrowings | |||
| Repayments of borrowings | |||
| Net (distribution) contribution to noncontrolling interest | |||
| Contingent consideration payments | |||
| Other | |||
| Net cash flow provided by (used in) financing activities | |||
| Net increase (decrease) in cash and cash equivalents | |||
| Effect of exchange rate changes on cash and cash equivalents | |||
| Cash and cash equivalents, beginning of the year | |||
| Cash and cash equivalents, end of the year |
42 line items · 3 reported periodsOriginal filing order · parentheses indicate negative amounts
Each column reflects this filing’s presentation. Original line items and period dates are preserved.
Arithmetic validation is incomplete for this statement. Source values remain individually inspectable.